Activities of Dalbavancin against a Worldwide Collection of 81,673 Gram-Positive Bacterial Isolates | Zendy

Douglas J. Biedenbach | Zendy; Jan M. Bell | Zendy; Hélio S. Sader | Zendy; John Turnidge | Zendy; Ronald N. Jones | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Activities of Dalbavancin against a Worldwide Collection of 81,673 Gram-Positive Bacterial Isolates

Author(s) -

Douglas J. Biedenbach,

Jan M. Bell,

Hélio S. Sader,

John Turnidge,

Ronald N. Jones

Publication year - 2009

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01453-08

Subject(s) - dalbavancin , gram , microbiology and biotechnology , gram positive bacterial infections , biology , gram negative bacterial infections , antibiotics , bacteria , staphylococcus aureus , vancomycin , genetics

Dalbavancin, a long-acting lipoglycopeptide, was evaluated against 81,673 isolates of staphylococci, enterococci, and streptococci collected from 33 countries during worldwide resistance surveillance (2002 to 2007). Regardless of susceptibility to oxacillin, comparable potencies for dalbavancin against Staphylococcus aureus and coagulase-negative staphylococci from all countries were noted (MIC(90), 0.06 to 0.12 microg/ml). Vancomycin-susceptible Enterococcus spp. had dalbavancin MIC(90)s comparable to those for staphylococci, whereas vancomycin-resistant strains were more resistant (MIC(50), >4 microg/ml). beta-Hemolytic and viridians group streptococci were very susceptible to dalbavancin (MIC(90), <or=0.03 microg/ml). Overall, dalbavancin was >or=16-fold more active than vancomycin against the monitored gram-positive species.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research